In 7% of patients, IDH1/IDH2 mutations persisted at high levels in complete remission, suggesting the presence in these patients of IDH mutations at the level of the preleukemic stem cell pool; five out of these seven patients relapsed or progressed to MDS [137]. This evidence concerns the gene IDH1 and myelodysplastic syndrome.